KraneShares MSCI All China Health Care Index ETF(KURE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KURE KraneShares MSCI All China Health Care Index ETF

盘前交易 08-14 04:14:32 EDT

18.66

+0.03

+0.16%

最高18.73	最低18.55	成交量9.41万
今开18.68	昨收18.63	日振幅0.94%
总市值1.07亿	流通市值1.07亿	总股本575.08万
成交额175.61万	换手率1.64%	流通股本575.08万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.66,"timestamp":1786651200000,"preClose":18.63,"halted":0,"volume":94114,"delay":0,"changeRate":0.0016103059581321062,"floatShares":5750778,"shares":5750778,"eps":0,"marketStatus":"盘前交易","change":0.03,"latestTime":"08-14 04:14:32 EDT","open":18.68,"high":18.725,"low":18.55,"amount":1756059.95004,"amplitude":0.009393,"askPrice":21.71,"askSize":100,"bidPrice":18,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786714200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":18.66,"sharesOutstanding":4750002,"nav":18.57,"aum":106779432.32,"dividendRate":0.038307,"bidAskSpread":0.005633,"postHourTrading":{"tag":"盘后","latestPrice":18.66,"preClose":18.66,"latestTime":"19:34 EDT","volume":58,"amount":1078.78,"timestamp":1786664051116,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.5364296749458324,"impliedVol":0.2881,"impliedVolPercentile":0.616},"requestUrl":"/m/hq/s/KURE/wiki","defaultTab":"wiki","newsList":[{"id":"2659118971","title":"信达生物联合美团买药探索即时零售 首发小规格新品","url":"https://stock-news.laohu8.com/highlight/detail?id=2659118971","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659118971?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:54","pubTimestamp":1786686872,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2097828631.EUR","LU2328871848.SGD","BK1589","BK1583","LU0455707207.USD","LU1188198961.HKD","HK0000165453.HKD","DRAG","LU2488822045.USD","LU0463099449.HKD","LU0326950275.SGD","MPNGY","BK1161","LU2097828557.USD","BK4209","LU2097828805.USD","LU2097828474.EUR","LU2242644610.SGD","03690","LU0502904849.HKD","01801","KURE","LU0244354667.USD","LU2097828714.EUR","BK4122","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659299118","title":"创新药概念集体回调 康方生物（09926）跌6.85%、维亚生物（01873）跌6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659299118","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659299118?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:51","pubTimestamp":1786686711,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念集体回调，康方生物 跌6.85%，维亚生物跌6.33%，思路迪医药股份跌6.15%，恒瑞医药跌5.10%，晶泰控股跌4.88%，凯莱英跌4.67%，亚盛医药跌4.04%，药明康德跌3.94%，百济神州跌3.92%。西南证券表示，CXO+创新药放量领涨，8-9月有望迎来业绩+临床数据共振。从产业链的角度，CXO板块投融资改善明显，26H1中国/全球医疗健康投融资分别676.47亿元/2416.43亿元，ADC、多肽、细胞基因治疗等新药物形式赛道持续火热，头部CXO公司海外订单复苏明显。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988233","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","LU0359202008.SGD","LU1720050803.USD","LU0634319403.HKD","KURE","LU0327786744.USD","LU2242644610.SGD","02228","BK1576","06821","LU0708995583.HKD","159992","LNGR","LU0561508036.HKD","IBBQ","BK1141","06160","BK1574","LU0588546209.SGD","LU1770034418.SGD","LU2476274720.SGD","06978","LU2476274308.USD","LU0348783233.USD","LU0828237510.HKD","01873","LU0052750758.USD","02359","LU0228659784.USD","LU0348766576.USD","LU1251922891.USD","LU0348784397.USD","LU0348827113.USD","IE00B5MMRT66.SGD","LU1961090484.USD","01244","01276","LU2778985437.USD","MEDX","LU2045819591.USD","BK1617","LU0359201612.USD","09926","06855","LU1794554557.SGD","LU2399975544.HKD","IE00B543WZ88.USD","LU0307460666.USD","LU0572944931.SGD","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659118892","title":"【特约大V】邓声兴：美CPI降温利好科技股，恒指料稳守两万六","url":"https://stock-news.laohu8.com/highlight/detail?id=2659118892","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659118892?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:21","pubTimestamp":1786684871,"startTime":"0","endTime":"0","summary":"美CPI降温利好科技股，恒指料稳守两万六。回顾2025年全年，集团研发费用约60亿元人民币，在研创新药及创新制剂项目逾200个，八大技术平台持续赋能管线推进。集团将于8月20日召开董事会批准中期业绩，近日亦持续回购股份，上半年累计回购逾2.5亿股。石药集团正处于业绩爆发、国际合作兑现、创新管线突破及回购护航四重利好交汇点，中线估值重构空间值得跟进。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/NDMwYzk0ZmE3ODZlM2UzYjdhOWIyNjc2MTkzNTM0OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NDMwYzk0ZmE3ODZlM2UzYjdhOWIyNjc2MTkzNTM0OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988222","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0880133367.SGD","03419","BK1521","LU1960683339.HKD","07500","07300","LU0067412154.USD","LU1993786604.SGD","LU0326950275.SGD","83115","07200","IE00B031HY20.USD","01093","513600","LU0140636845.USD","02800","IE0008368742.USD","LU0314109678.HKD","LU0501845795.SGD","LU1152091168.USD","BK1191","LU0072913022.USD","LU1226287875.USD","LU0315179316.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","MCHmain","03115","BK1515","HSTECH","IE00B543WZ88.USD","KURE","03037","HK0000165453.HKD","LU1226287529.USD","IE00BZ08YT58.USD","LU1008478684.HKD","LU1813983027.USD","LU1807302812.USD","IE00BZ08YS42.EUR","LU2039709279.SGD","LU1226288253.USD","HSI","HHImain","LU1951186391.HKD","SG9999004220.SGD","02833","82800","IE0008369823.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","09115","LU1152091754.HKD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU0348783233.USD","LU0417516571.SGD","LU0561508036.HKD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU1303224171.USD","02196","BK1191","LU1770034418.SGD","LU0828237510.HKD","LU0634319403.HKD","LU2778985437.USD","QTOC","02268","LU0348827113.USD","LU0348784397.USD","LU0640798160.USD","BK1500","LU1961090484.USD","BK1585","LU2476274720.SGD","VTHR","ARTY","03933","KCE","LU0417516738.SGD","02367","SG9999004311.SGD","LU2328871848.SGD","BK1515","06160","KURE","AGIX","02228","01530","CHAT","LU0348766576.USD","LU2476274308.USD","09926","01099","06821","BK1197","LU1719994722.HKD","AIPO","601066","LU0348825331.USD","LU0348735423.USD","01477","01789"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168507","title":"百济神州（688235）披露授出受限制股份单位公告，8月13日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168507?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:03","pubTimestamp":1786629800,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，百济神州报收于292.18元，较前一交易日下跌0.5%，最新总市值为4506.25亿元。该股当日开盘291.0元，最高301.96元，最低290.11元，成交额达20.95亿元，换手率为6.14%。近日，公司披露港股公告显示，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划向三百六十二名承授人授出合计40,764股美国存托股份的受限制股份单位，相当于529,932股普通股，约占公司当前已发行股份总数的0.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","BK0239","LU1969619763.USD","BK1583","688235","KURE","LU0828237510.HKD","LU1770034418.SGD","06160","BK1588","LU2328871848.SGD","LU0307460666.USD","LU0228659784.USD","LU1251922891.USD","LU1303224171.USD","LU0588546209.SGD","BK1161","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168288","title":"亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168288","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168288?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:13","pubTimestamp":1786626780,"startTime":"0","endTime":"0","summary":"中国苏州2026年8月13日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司管理层将出席于2026年8月17日-19日在上海浦东丽思卡尔顿酒店举办的Evercore第二届中国生物科技峰会。会议期间，公司管理层将参与由Evercore研究团队主持的炉边谈话，并开展一对一投资者交流会。因此，该等前瞻性陈述不应被视为对未来事件的预测。无论出现新信息、未来事件或其他情况，亚盛医药均无义务更新或修订任何前瞻性陈述。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["KURE","AAPG","BK4127","BK1161","EVR","03069","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152904","title":"别慌！机构资金都流向了这里！","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152904","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659152904?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:23","pubTimestamp":1786623796,"startTime":"0","endTime":"0","summary":"今天（8月13日），A股早盘三大指数集体高开，CPO等板块全线走强，“易中天”强势上涨，封板个股比比皆是。然而，下午2点左右，画风突变，上午追高的资金，午后被悉数套牢，截至收盘，仅创新药一枝独秀。那么，科技冲高回落，医药逆势爆发，这究竟发生了什么？今天这篇文章，笔者将逐一拆解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840675371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840675371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0828237510.HKD","LU1770034418.SGD","LU1719994722.HKD","06978","MEDX","06160","399300","LU1251922891.USD","83130","BK1588","LU2328871848.SGD","CPI","LU0588546209.SGD","BK4007","BK1500","BD","03130","BK1147","LU0307460666.USD","07233","IBBQ","LU1303224171.USD","82846","03188","KURE","OCS","LU0228659784.USD","BK1583","159982","83188","BK1574","LNGR","LU1969619763.USD","BK1161","02846","02827"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659137609","title":"百济神州(06160)授出合共40764股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2659137609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659137609?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:56","pubTimestamp":1786611374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划的条款授予362名承授人合共40,764股美国存托股份受限制股份单位。该等受限制股份单位相当于529,932股股份，约占本公告之日公司发行股份总数的0.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","LU1303224171.USD","BK1588","LU0307460666.USD","BK1161","06160","KURE","BK4585","BK4588","LU1719994722.HKD","BK4139","LU1770034418.SGD","LU0588546209.SGD","BK4526","BK1500","LU1969619763.USD","LU0828237510.HKD","LU2328871848.SGD","BK0239","LU1251922891.USD","688235","BK1583","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659577187","title":"港股异动 | 石药集团(01093.HK)涨近4% 收到阿斯利康3000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2659577187","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659577187?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:55","pubTimestamp":1786589707,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0880133367.SGD","LU1993786604.SGD","IE0008369823.USD","LU0501845795.SGD","LU1152091754.HKD","LU0315179316.USD","01093","LU1152091168.USD","LU1807302812.USD","IE00BZ08YT58.USD","LU0326950275.SGD","BK1515","LU1328277881.USD","IE00B031HY20.USD","LU1226288170.HKD","IE00B543WZ88.USD","LU0140636845.USD","LU1951186391.HKD","LU1226287529.USD","SG9999004220.SGD","BK1191","HK0000165453.HKD","LU1008478684.HKD","BK1521","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1226288253.USD","LU1813983027.USD","LU0072913022.USD","LU0067412154.USD","KURE","LU2039709279.SGD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU1226287792.SGD","LU1960683339.HKD","LU1226287875.USD","IE0008368742.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658707129","title":"石药集团(01093)：2018年股份奖励计划受托人变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2658707129","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658707129?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:15","pubTimestamp":1786540533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，根据计划规则，2018年股份奖励计划的受托人(受托人)变更将自2026年8月12日起生效。本公司将委聘中银国际信托( 香港 )有限公司(中银国际信托)作为受托人，以取代中银国际英国保诚信托有限公司(中银国际英国保诚)，而本公司与中银国际信托将订立经修订及重列的信托契约，以落实有关变更。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU1328277881.USD","BK1515","IE00B031HY20.USD","LU0501845795.SGD","LU0067412154.USD","IE00BZ08YS42.EUR","LU1008478684.HKD","BK1521","LU0314109678.HKD","IE00BZ08YT58.USD","LU1226287792.SGD","LU0072913022.USD","KURE","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","BK1191","LU0326950275.SGD","IE00B543WZ88.USD","LU1813983027.USD","LU1226287529.USD","LU2039709279.SGD","IE0008368742.USD","01093","LU1993786604.SGD","LU1226287875.USD","LU1152091754.HKD","LU1960683339.HKD","IE0008369823.USD","LU1152091168.USD","LU0315179316.USD","LU0880133367.SGD","LU0140636845.USD","LU1226288170.HKD","LU1226288253.USD","LU1807302812.USD","HK0000165453.HKD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970199","title":"康方生物(09926)：依达方®(依沃西，PD-1/VEGF)第三个适应症上市申请获得国家药品监督管理局批准，用于一线治疗SQ-NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970199","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658970199?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:01","pubTimestamp":1786539717,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，由公司自主研发的全球首创双特异性抗体依达方联合化疗用于一线治疗晚期鳞状非小细胞肺癌的新药上市申请，已获得中国国家药品监督管理局批准上市。这是依沃西获批上市的第三个适应症。依沃西联合化疗一线治疗sq-NSCLC新适应症的获批上市，是基于依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期sq-NSCLC的随机、对照、多中心III期临床研究中获得的显著阳性结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348767384.USD","LU2399975544.HKD","LU2476274720.SGD","LU0540923850.HKD","BK4023","LU0417516571.SGD","IPOS","LU0561508036.HKD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0348783233.USD","PD","LU1169590202.USD","LU1794554557.SGD","LU2778985437.USD","LU0348827113.USD","BK1161","LU0348784397.USD","BK1574","LU0348735423.USD","LU0417516902.SGD","LU2488822045.USD","LU1169589451.USD","IE00BPRC5H50.USD","KURE","09926","LU1961090484.USD","IE00B543WZ88.USD","LU0348825331.USD","LU1720050803.USD","LU0634319403.HKD","LU0348766576.USD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658797270","title":"石药集团(01093.HK)收到与阿斯利康就siRNA药物开发订立的合作、选择权及授权协议项下3000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658797270","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658797270?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:19","pubTimestamp":1786537187,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1226287875.USD","BK1515","LU0315179316.USD","IE00BZ08YT58.USD","LU1951186391.HKD","KURE","LU1960683339.HKD","LU1993786604.SGD","LU1813983027.USD","LU0067412154.USD","LU0880133367.SGD","SG9999004220.SGD","IE00BZ08YS42.EUR","LU1152091754.HKD","BK1521","LU1226287792.SGD","LU1226288170.HKD","LU0314109678.HKD","IE00B031HY20.USD","LU0072913022.USD","LU1008478684.HKD","LU1226288253.USD","LU2039709279.SGD","LU1807302812.USD","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","LU1328277881.USD","IE00B543WZ88.USD","IE0008369823.USD","LU1226287529.USD","LU0140636845.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1152091168.USD","LU0326950275.SGD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120259263","title":"石药集团：与阿斯利康合作获3000万美元预付款，2026年8月12日到账","url":"https://stock-news.laohu8.com/highlight/detail?id=1120259263","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120259263?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:18","pubTimestamp":1786537091,"startTime":"0","endTime":"0","summary":"石药集团（CSPC PHARMA）宣布，根据双方签署的合作协议，公司已于2026年8月12日收到来自阿斯利康（AstraZeneca）的3000万美元首期付款。这笔款项标志着合作正式启动，彰显了石药集团在药物研发领域的国际认可度。通过此次合作，石药集团不仅获得了可观的财务支持，更打开了全球医药市场的新通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU1226287529.USD","HK0000165453.HKD","LU0315179316.USD","LU1960683339.HKD","IE00B031HY20.USD","LU0501845795.SGD","SG9999004220.SGD","LU1813983027.USD","LU1008478684.HKD","LU1152091168.USD","LU1951186391.HKD","BK1521","LU1152091754.HKD","LU1226288253.USD","LU0326950275.SGD","IE0008369823.USD","LU1807302812.USD","LU2039709279.SGD","IE00B543WZ88.USD","LU0880133367.SGD","LU0140636845.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE0008368742.USD","LU1993786604.SGD","LU0314109678.HKD","LU1226287792.SGD","LU0067412154.USD","IE00BZ08YT58.USD","BK1191","01093","LU1328277881.USD","KURE","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1226287875.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990023","title":"石药集团：SYS6063用于治疗SLE的Ⅰ期临床试验在中国首家中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990023","media":"第一财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658990023?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:17","pubTimestamp":1786450635,"startTime":"0","endTime":"0","summary":"【石药集团：SYS6063用于治疗SLE的Ⅰ期临床试验在中国首家中心正式启动】石药集团在港交所公告，公司开发的SYS6063用于治疗复发难治性系统性红斑狼疮（SLE）的Ⅰ期临床试验已在中国首家中心正式启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838106386.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838106386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0008368742.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU0072913022.USD","LU1008478684.HKD","LU1813983027.USD","LU0326950275.SGD","PSYK","IE0008369823.USD","LU0314109678.HKD","LU0501845795.SGD","01093","IE00B5MMRT66.SGD","SG9999004220.SGD","BK1515","MDTX","IE00B543WZ88.USD","LU1152091754.HKD","BK4077","LU1226288253.USD","LU0140636845.USD","LU1960683339.HKD","IBBQ","BK1521","IBBJ","LU1993786604.SGD","LU0315179316.USD","LU0067412154.USD","LU1951186391.HKD","LU2039709279.SGD","IE00B031HY20.USD","BMED","HK0000165453.HKD","LU1807302812.USD","LU1328277881.USD","LU1226287792.SGD","LU1226287529.USD","LU1226287875.USD","LU1152091168.USD","SLE","KURE","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1226288170.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189392087","title":"石药集团启动SYS6063用于中国难治性系统性红斑狼疮的I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1189392087","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189392087?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:03","pubTimestamp":1786449807,"startTime":"0","endTime":"0","summary":"石药集团正式宣布，其自主研发的候选药物SYS6063已在中国获批开展I期临床试验。该试验旨在评估SYS6063针对复发或难治性系统性红斑狼疮（SLE）患者的安全性与初步疗效。这一重要进展标志着石药集团在自身免疫性疾病领域的创新研发迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072913022.USD","LU0501845795.SGD","IE00B031HY20.USD","LU0140636845.USD","LU0880133367.SGD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU1226287529.USD","LU0067412154.USD","IE00BZ08YT58.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU1152091754.HKD","LU1960683339.HKD","LU0315179316.USD","LU1152091168.USD","BK1191","LU1008478684.HKD","LU1226287875.USD","LU0326950275.SGD","01093","LU1226287792.SGD","BK1521","LU1807302812.USD","KURE","BK1515","LU2039709279.SGD","IE0008368742.USD","LU1226288253.USD","HK0000165453.HKD","LU1328277881.USD","IE00BZ08YR35.GBP","LU1993786604.SGD","IE0008369823.USD","SG9999004220.SGD","LU1813983027.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992720","title":"吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992720","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658992720?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:25","pubTimestamp":1786447500,"startTime":"0","endTime":"0","summary":"8月11月，A股、港股大幅回调，医药资产受大市影响整体冲高回落，其中创新药产业链韧性凸显，批量成功收红。成份股再鼎医药领涨5.28%，权重龙头百济神州涨2.63%斩获6连阳，股价创年内新高！基金管理人评估的药ETF华宝的风险等级为R3-中风险，适宜平衡型及以上的投资者，港股通医疗ETF华宝、港股通创新药ETF华宝及其联接基金的风险等级为R4-中高风险，适宜积极型及以上的投资者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-11/doc-inimyaaf7389173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","159828","LU1719994722.HKD","LU0228659784.USD","LU1251922891.USD","FLHK","BK4139","KURE","159316","BK1588","LU2328871848.SGD","LU0588546209.SGD","BK4585","ONC","BK1161","LU0307460666.USD","LU0828237510.HKD","603087","BK1583","LU1770034418.SGD","LU1969619763.USD","688235","BK1500","BK4588","BK0239","LU1303224171.USD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993724","title":"百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993724","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658993724?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:35","pubTimestamp":1786437325,"startTime":"0","endTime":"0","summary":"8月10日，由百济神州与安进公司共同负责中国（不含港澳台地区）商业化开发的安泰适（注射用塔拉妥单抗）正式投入临床使用。截至8月10日，全国17个城市29家医疗机构已开出首批处方。据悉，塔拉妥单抗为首个且目前唯一获批的靶向DLL3和CD3的T细胞衔接器（TCE），于8月7日启动供应，首批复盖全国80个城市、超200家医疗机构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837896326.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837896326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","06160","LU1251922891.USD","LU1303224171.USD","BK4526","KURE","BK0239","LU0828237510.HKD","BK1161","LU1770034418.SGD","LU0228659784.USD","LU1719994722.HKD","LU1969619763.USD","BK1500","ONC","688235","LU0307460666.USD","BK1588","BK4585","BK4588","LU0588546209.SGD","BK4139","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161961","title":"市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0109394709.USD","LU1720051017.SGD","LU2298322129.HKD","BK4139","LU1854103824.USD","688235","LU1854104046.USD","ON","IDNA","LU0889565916.HKD","PTH","LU1720051108.HKD","IE00BD6J9T35.USD","IE00BFTCPJ56.SGD","LU0348723411.USD","LU2357305700.SGD","LU0320765992.SGD","LU1983260115.SGD","BK4141","KURE","BK4585","BK4605","LU0588546209.SGD","IE0009355771.USD","IE0002141913.USD","LU1861219969.SGD","LU1978683503.SGD","IE00BJT1NW94.SGD","RVMD","IE00BFMHRM44.USD","LU1251922891.USD","BBH","IE0009354923.USD","LU1548497426.USD","LU1861214812.USD","BK0239","LU2360107325.USD","IE00B2B36J28.USD","BK4588","LU1770034418.SGD","IE00BJJMRZ35.SGD","CANC","LU1861215975.USD","BK4512","LU0724618433.USD","BK1583","06160","BK1588","LU0124384867.USD","IE00BZ199S13.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521","LU0072913022.USD","BK1588","159992","LU0315179316.USD","01093","03692","LU0326950275.SGD","LNGR","IE00B543WZ88.USD","KURE","01548","LU1226288170.HKD","LU2125910500.SGD","IE00B5MMRT66.SGD","LU0880133367.SGD","HK0000320223.HKD","06855","LU1152091168.USD","MEDX","LU1813983027.USD","LU2328871848.SGD","HK0000306685.HKD","LU1226287792.SGD","BK1576","02228","06978","BK1161","02359","BK1515","IE00BZ08YT58.USD","LU1993786604.SGD","LU1303224171.USD","BK1583","09969","BK1617","06160","LU2242644610.SGD","BK1500","02268","02410","IE00B031HY20.USD","LU1951186391.HKD","LU2488822045.USD","LU1226287875.USD","IBBQ","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966537","title":"港股医药股多数走强 金斯瑞生物科技涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966537","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658966537?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:33","pubTimestamp":1786415604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KURE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kraneshares.com/kure/","stockEarnings":[{"period":"1week","weight":0.0681},{"period":"1month","weight":0.0836},{"period":"3month","weight":0.1427},{"period":"6month","weight":0.0253},{"period":"1year","weight":-0.0707},{"period":"ytd","weight":0.0951}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.011813},{"month":2,"riseRate":0.625,"avgChangeRate":0.040467},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.011251},{"month":4,"riseRate":0.555556,"avgChangeRate":0.009997},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.006548},{"month":6,"riseRate":0.555556,"avgChangeRate":0.020849},{"month":7,"riseRate":0.666667,"avgChangeRate":0.022663},{"month":8,"riseRate":0.555556,"avgChangeRate":-0.010862},{"month":9,"riseRate":0.5,"avgChangeRate":0.002438},{"month":10,"riseRate":0.5,"avgChangeRate":-0.020874},{"month":11,"riseRate":0.5,"avgChangeRate":0.01787},{"month":12,"riseRate":0.375,"avgChangeRate":-0.04543}],"exchange":"ARCA","name":"KraneShares MSCI All China Health Care Index ETF","nameEN":"KraneShares MSCI All China Health Care Index ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KraneShares MSCI All China Health Care Index ETF(KURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供KraneShares MSCI All China Health Care Index ETF(KURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"KraneShares MSCI All China Health Care Index ETF,KURE,KraneShares MSCI All China Health Care Index ETF股票,KraneShares MSCI All China Health Care Index ETF股票老虎,KraneShares MSCI All China Health Care Index ETF股票老虎国际,KraneShares MSCI All China Health Care Index ETF行情,KraneShares MSCI All China Health Care Index ETF股票行情,KraneShares MSCI All China Health Care Index ETF股价,KraneShares MSCI All China Health Care Index ETF股市,KraneShares MSCI All China Health Care Index ETF股票价格,KraneShares MSCI All China Health Care Index ETF股票交易,KraneShares MSCI All China Health Care Index ETF股票购买,KraneShares MSCI All China Health Care Index ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KraneShares MSCI All China Health Care Index ETF(KURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供KraneShares MSCI All China Health Care Index ETF(KURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}